A. Bryant

发表

A functional genomic analysis of type 3 Streptococcus pneumoniae virulence

M. Lonetto, D. Holden, G. Lau, 2001, Molecular microbiology.

rho Is Not Essential for Viability or Virulence inStaphylococcus aureus

M. Rosenberg, A. Marra, D. Gentry, 2001, Antimicrobial Agents and Chemotherapy.

Identification, Evolution, and Essentiality of the Mevalonate Pathway for Isopentenyl Diphosphate Biosynthesis in Gram-Positive Cocci

James R. Brown, S. Iordanescu, M. Gwynn, 2000, Journal of bacteriology.

Inhibition of Filamentation Can Be Used To Treat Disseminated Candidiasis

J. Lopez-Ribot, C. Monteagudo, A. Monreal, 2006, Antimicrobial Agents and Chemotherapy.

Lipid modification of prelipoproteins is dispensable for growth in vitro but essential for virulence in Streptococcus pneumoniae.

D. Holmes, J. R. Brown, K. Ingraham, 2001, FEMS microbiology letters.

A genomic analysis of two‐component signal transduction in Streptococcus pneumoniae

James R. Brown, K. Koretke, N. Wallis, 2000, Molecular microbiology.

Genetic characterization of gram-positive homologs of the XerCD site-specific recombinases.

A. Lupas, R. Lunsford, D. Holmes, 2000, Journal of molecular microbiology and biotechnology.

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.

M. Currie, C. Kurtz, G. Hannig, 2010, Life sciences.

The bacA gene, which determines bacitracin susceptibility in Streptococcus pneumoniae and Staphylococcus aureus, is also required for virulence.

R. Lunsford, N. Wallis, D. Holmes, 2000, Microbiology.

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

M. Currie, C. Kurtz, G. Hannig, 2010, European journal of pharmacology.

Gastrointestinal pain: Unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation

M. Currie, E. Ustinova, E. Liong, 2013, PAIN®.

Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

M. Currie, C. Kurtz, G. Hannig, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Guanylate cyclase C‐mediated antinociceptive effects of linaclotide in rodent models of visceral pain

M. Currie, E. Mayer, H. Eutamene, 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux

M. Currie, C. Lunte, C. Kurtz, 2015, The Journal of Pharmacology and Experimental Therapeutics.

MRP 4 Modulation of the Guanylate Cyclase-C / cGMP Pathway : Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux s

M. Currie, C. Lunte, C. Kurtz, 2015 .

Pharmacological Properties, Metabolism and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation #

C. Kurtz, G. Hannig, D. James, 2012 .

The srhSR gene pair from Staphylococcus aureus: genomic and proteomic approaches to the identification and characterization of gene function.

S. Carr, R. Lunsford, R. Annan, 2001, Biochemistry.

Characterization of the Streptococcus pneumoniae NADH oxidase that is required for infection.

M. Lonetto, M. Rosenberg, D. Holden, 2001, Microbiology.

A Global Approach to Identify Novel Broad-Spectrum Antibacterial Targets among Proteins of Unknown Function

James R. Brown, P. Warren, R. Lunsford, 2004, Journal of Molecular Microbiology and Biotechnology.

Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain

M. Currie, C. Kurtz, G. Hannig, 2014, Front. Mol. Neurosci..

Identification, Evolution, and Essentiality of the Mevalonate Pathway for Isopentenyl Diphosphate Biosynthesis in Gram-Positive Cocci

James R. Brown, S. Iordanescu, M. Gwynn, 2000, Journal of bacteriology.

Essentiality, Expression, and Characterization of the Class II 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase ofStaphylococcus aureus

Martin Rosenberg, Daniel Sylvester, R. Lunsford, 2000, Journal of bacteriology.

ANTINOCICEPTIVE ACTIONS OF MD-1100, A NOVEL THERAPEUTIC AGENT FOR c-IBS, IN ANIMAL MODELS OF VISCERAL PAIN: 867

M. Currie, L. Buéno, S. Mahajan-Miklos, 2004 .